AIM: This study was carried out to determine whether rectal bleeding is related to stage of bowel cancer and whether earlier diagnosis and treatment are associated with improved survival. METHOD: Eight hundred and forty-five patients were identified in the Wessex Bowel Cancer Audit (1991-1994). Presenting symptoms were identified from case notes. Outcome measures included 5-year survival, Dukes' stage, metastatic disease at surgery and time from onset of symptoms to treatment, in patients presenting with rectal bleeding or other symptoms and signs. RESULTS: Six hundred and seventy-six (80%) of 845 patient case notes were reviewed. Of these, 408 (60.4%) patients had rectal or sigmoid cancer, and 255 (62.5%) of these 408 patients, who presented with rectal bleeding, had significantly earlier stage disease than those with a change in bowel habit and/or abdominal pain (Dukes' stage A: 23.1%vs 3.6%; Dukes' stage D: 14.5%vs 23.4%; P < 0.001), fewer metastases visible at surgery (14.9%vs 22.6%; P < 0.001) and significantly better 5-year survival (54.8%vs 40.9%; P < 0.001). There was no further significant improvement in 5-year survival in patients treated within 6 months of the onset of symptoms (55.1%vs 53.5%). Hazard ratios showed that 5-year survival was independently associated with age, Dukes' stage and emergency treatment, but not with rectal bleeding, change in bowel habit, abdominal pain or delay in treatment. CONCLUSION: Bowel cancer patients presenting with rectal bleeding had earlier stage disease and significantly better survival than patients presenting with a change in bowel habit or abdominal pain. There was no reduction in 5-year survival in those patients who had a delay in treatment for > 6 months from the onset of symptoms.
AIM: This study was carried out to determine whether rectal bleeding is related to stage of bowel cancer and whether earlier diagnosis and treatment are associated with improved survival. METHOD: Eight hundred and forty-five patients were identified in the Wessex Bowel Cancer Audit (1991-1994). Presenting symptoms were identified from case notes. Outcome measures included 5-year survival, Dukes' stage, metastatic disease at surgery and time from onset of symptoms to treatment, in patients presenting with rectal bleeding or other symptoms and signs. RESULTS: Six hundred and seventy-six (80%) of 845 patient case notes were reviewed. Of these, 408 (60.4%) patients had rectal or sigmoid cancer, and 255 (62.5%) of these 408 patients, who presented with rectal bleeding, had significantly earlier stage disease than those with a change in bowel habit and/or abdominal pain (Dukes' stage A: 23.1%vs 3.6%; Dukes' stage D: 14.5%vs 23.4%; P < 0.001), fewer metastases visible at surgery (14.9%vs 22.6%; P < 0.001) and significantly better 5-year survival (54.8%vs 40.9%; P < 0.001). There was no further significant improvement in 5-year survival in patients treated within 6 months of the onset of symptoms (55.1%vs 53.5%). Hazard ratios showed that 5-year survival was independently associated with age, Dukes' stage and emergency treatment, but not with rectal bleeding, change in bowel habit, abdominal pain or delay in treatment. CONCLUSION:Bowel cancerpatients presenting with rectal bleeding had earlier stage disease and significantly better survival than patients presenting with a change in bowel habit or abdominal pain. There was no reduction in 5-year survival in those patients who had a delay in treatment for > 6 months from the onset of symptoms.
Authors: Sanja Percac-Lima; Lydia E Pace; Kevin H Nguyen; Charis N Crofton; Katharine A Normandin; Sara J Singer; Meredith B Rosenthal; Alyna T Chien Journal: J Gen Intern Med Date: 2018-01-04 Impact factor: 5.128
Authors: Antonieta Medina-Lara; Bogdan Grigore; Ruth Lewis; Jaime Peters; Sarah Price; Paolo Landa; Sophie Robinson; Richard Neal; William Hamilton; Anne E Spencer Journal: Health Technol Assess Date: 2020-11 Impact factor: 4.014
Authors: Lydia E Pace; Sanja Percac-Lima; Kevin H Nguyen; Charis N Crofton; Katharine A Normandin; Sara J Singer; Meredith B Rosenthal; Alyna T Chien Journal: J Gen Intern Med Date: 2019-04-22 Impact factor: 5.128
Authors: Olusegun Isaac Alatise; Omobolaji O Ayandipo; Ademola Adeyeye; Ken Seier; Akinwunmi O Komolafe; Matthew O Bojuwoye; Oludapo O Afuwape; Ann Zauber; Adeleye Omisore; Samuel Olatoke; Adegboyega Akere; Olusola Famurewa; Mithat Gonen; David O Irabor; T Peter Kingham Journal: Cancer Date: 2018-04-12 Impact factor: 6.860
Authors: Chanpreet S Arhi; Elaine M Burns; Alex Bottle; George Bouras; Paul Aylin; Paul Ziprin; Ara Darzi Journal: Br J Gen Pract Date: 2020-06-25 Impact factor: 5.386
Authors: R D Neal; P Tharmanathan; B France; N U Din; S Cotton; J Fallon-Ferguson; W Hamilton; A Hendry; M Hendry; R Lewis; U Macleod; E D Mitchell; M Pickett; T Rai; K Shaw; N Stuart; M L Tørring; C Wilkinson; B Williams; N Williams; J Emery Journal: Br J Cancer Date: 2015-03-31 Impact factor: 7.640
Authors: E Visser; A G Leeftink; P S N van Rossum; S Siesling; R van Hillegersberg; J P Ruurda Journal: Ann Surg Oncol Date: 2016-03-24 Impact factor: 5.344